Riskpilot← Back to searchSign inGet full accessWIIK PHARMA ApS
APSActiveCVR 36481315Bogøvej 15Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20158 employeeswww.wiikpharma.dk
Revenue 2024
DKK 8,7M
+30% vs 2023
EBITDA margin
64.2%
+49% vs 2023
Equity ratio
38.6%
Financial strength
Net profit 2024
DKK 4,4M
+57% vs 2023
| Revenue | DKK 8,7M | +30% |
| EBITDA | DKK 5,6M | +49% |
| Net profit | DKK 4,4M | +57% |
| Total assets | DKK 12,1M | +30% |
| Equity | DKK 4,7M | +62% |
| Employees | 8 | — |
Legal name
WIIK PHARMA ApS
CVR number
36481315
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
2. januar 2015
Share capital
DKK 50.000
Employees
8 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren
Company purpose
Selskabets formål er at drive handel med medicinsk udstyr til hospitaler.
Address
Bogøvej 15
Phone
+4531367080
Website
www.wiikpharma.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3.403 | 3.172 | 4.088 | 6.666 | 8.678 |
| Staff expenses | -1.627 | -1.830 | -2.709 | -2.940 | -3.110 |
| EBITDA | 1.776 | 1.343 | 1.379 | 3.726 | 5.568 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | 1.776 | 1.343 | 1.379 | 3.726 | 5.568 |
| Net financials | -34 | -59 | -48 | -134 | 59 |
| Profit before tax | 1.742 | 1.283 | 1.331 | 3.593 | 5.628 |
| Tax | 388 | 285 | 300 | 796 | 1.242 |
| Net profit | 1.354 | 998 | 1.031 | 2.796 | 4.385 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 5.225 | 4.497 | 4.863 | 9.335 | 12.150 |
| Equity | 1.416 | 1.065 | 1.101 | 2.897 | 4.686 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3.808 | 3.433 | 3.762 | 6.438 | 7.464 |
| Total debt | 3.808 | 3.433 | 3.762 | 6.438 | 7.464 |
EBITDA margin
64.2%
This company
15.8%
Market median
+306% vs market
20202024
Equity ratio
38.6%
This company
38.2%
Market median
+1% vs market
20202024
Return on equity
93.6%
This company
18.4%
Market median
+409% vs market
20202024
Net profit margin
50.5%
This company
8.1%
Market median
+523% vs market
20202024
Asset turnover
0.71×
This company
1.12×
Market median
-37% vs market
20202024
Debt / equity
1.59×
This company
0.62×
Market median
-156% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
RW Chief Executive Officer | Chief Executive Officer | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2018 | |
| Chairman | 2018 | |
| Former (1) | ||
| Board of Directors | 2018 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 66.67–89.99% | 66.67–89.99% | 2025 | |
| Company | 15–19.99% | 15–19.99% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Yacoub Amin Invest ApS
WIIK PHARMA ApS Board members of WIIK PHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rune Wiik Kristensen | Chief Executive Officer | 0 companies |
| Mette Wiik Kristensen | Board of Directors | 0 companies |
| Yacoub Youssef Ibrahim Amin | Board of Directors | 0 companies |
| Bernt Skov Jensen | Chairman | 0 companies |